Enfuvirtide: First drug of a new family of antiretroviral agents;Enfuvirtida: Primer fármaco de una nueva familia de antirretro virales

Farmacia Hospitalaria

Volumn 29, Issue 6, 2005, Pages 375-383

  Espona, Mercè ^a   Ferrandez O ^a   Grau, S ^a   Carmona, A ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Clinical trials; Enfuvirtide; Fusion inhibitors; HAART; HIV; T 20

Indexed keywords

6 HYDROXYCHLORZOXAZONE; ANTIRETROVIRUS AGENT; CAFFEINE; DAPSONE; DEBRISOQUINE; ENFUVIRTIDE; HYDROXYLAMINE; MEPHENYTOIN; RIFAMPICIN; RITONAVIR;

APPETITE DISORDER; ARTICLE; CONJUNCTIVITIS; DIARRHEA; DRUG MECHANISM; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; INSOMNIA; MYALGIA; NAUSEA; NEUROPATHY; PAIN; PNEUMONIA; PRURITUS; SINUSITIS; TREATMENT FAILURE; VIRUS CELL INTERACTION;

EID: 32244434266     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(05)73699-0     Document Type: Review

References (35)

1. Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, et al. Changes in the rate of genotypic resistance on retroviral drugs in Spain. AIDS 2001; 15: 1894-6.
2. Fung HB, Guo Yi. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004; 26: 352-78.
3. Kwong PD, Waytt R, Robinson J, Sweets RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and neutralizing human antibody. Nature 1998; 393: 648-59.
4. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent supresión of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-7.
5. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-93.
6. Lalezari JP, Eron JJ, Carlson M, Cohen C, Dejesus E, Arduino RC, et al. A phase II clinical study of the long-term safety and antiviral of enfuvirtide-based antiretrovial therapy. AIDS 2003; 17: 691-8.
7. Patel IH, Lalezari J, Dorr A, Hawker N, Siddique Z, Kolis S, et al. T-20 is optimally absorbed from 3 different subcutaneous injection sites (abstract). En: XIV International AIDS Conference, 2002.
8. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 198-211.
9. Roche Pharmaceuticals. Investigator brochure T-20 (Ro 29-9800), 5th version. Nutley, NJ;2002.
10. Leen C, Wat C, Nieforth K. Pharmacokinetics of enfuvirtide in a patient with impaired renal function. Clin Infect Dis 2004; 39: 119-21.
11. Bellibas E, Siddique Z, Dorr A, Bertasso A, Sista PR, Dolis S, et al. Poster 841. Pharmacokinetics of enfuvirtide in pediatric HIV patients receiving combination therapy (abstract). En: 2nd IAS Conference on HIV Pathogenesis and Treatment. París, 2003.
12. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, et al. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol & Therapeutics 2003; 74: 569-80.
13. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trotier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
14. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
15. Battegay M, DeMasi R, Delehanty J, Chung J, Huson L, Salgo M for the TORO 1 and TORO 2 Study Groups. Antivir Ther 2003; 8: S340. Book of abstracts:574.
16. Hornberger J, Green J. Clinical prognosis of enfuvirtide in combination with an optimised background regimen among categories of baseline CD4 cell count and HIV antiretroviral resistance. Antivir Ther 2003; 8: S310. Book of abstracts: 478.
17. Montaner J, Chung J, Guimaraes D, DeMasi R, Gafoor Z, Salgo M. A treatment staging proposal derived from a post hoc analysis of the 48 week results from the TORO studies. In: XV International AIDS Conference. Bangkok, 2004.
18. Arasteh K, Lazzarin A, Clotet B, Lalezari J, Cooper D, Henry K, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. En: 15th International AIDS Conference. Bangkok, 2004. Book of abstracts: 1058.
19. Greenberg ML, Sista P, Miralles GD, Melby T, Davidson K, Jin L, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a phase I/II dose-ranging monotherapy trial of T-1249. Antiviral ther 2002; 7:S106. Book of abstracts: 128.
20. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp 120. J Virol 2001; 75: 8605-14.
21. Greenberg ML, McDanal CB, Stanfield-Oakley S, Jin L, Tremblay C, Sista P, et al. Virus sensitivity to T-20 is independent of coreceptor useage. En: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001. Book of abstracts: 473.
22. Rimsky L, Shugars D, Matthews T. Determinants of HIV type I resistance to gp41-derived inhibitory peptides. J Virol 1998; 72: 986-93.
23. Sista P, Melby T, Greenberg S, Davidson D, Jin L, Mosier S, et al. Characterization of baseline and treatment emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir Ther 2002; 7: S16-7.
24. Mink M, Greenberg ML, Mosier S, Januripalli S, Davidson D, Jin L, et al. Impact of HIV-1 gp 41 amino acid substitutions (position 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. Antivir Ther 2002; 7: S17-8.
25. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
26. Lu J, Cammack N, Kuritzkes D. Fitness of HIV-1 clinical isolates resistant to enfuvirtide. Antiviral Ther 2002; 7: S56.
27. Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther; 2003; 73: 558-68.
28. Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43: 1382-91.
29. Boyd M, Ruxrungtham K, Zhang X, Bellibas E, Buss NE, Patel IH. Enfuvirtide: investigations on the drug interaction potential in HIV-infected patients (abstract). En: 10th Conference on Retroviruses and Opportunistic Infections. Boston, 2003.
30. Drobnes C, Fang L, Nelson E, Trae A, Salgo M, Delehanty J. Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. In: 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002, San Diego, CA, page 262 (abstract H-171).
31. Myers SA, Selim A, Mcdaniel M, Hall R, Bartlett J, True AL, et al. A prospective clinical and histological examination of injection sites with the fusion inhibitor enfuvirtide (ENF). In: 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002, San Diego, CA, page 262 (abstract H-2015).
32. Ball RA, Kinchelow T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 2003; 49: 826-31.
33. Shah ND, Hoffman JM, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future drugs expenditures. Am J Health Syst Pharm 2003; 60: 137-49.
34. Steinbrook R. HIV infection - a new drug and new cost. N Engl J Med 2003; 348: 2171-2.
35. Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005; 39: 69-77.